<?xml version="1.0" encoding="ISO-8859-1"?><!DOCTYPE ichicsr>
<ichicsr lang="en">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>78949</messagenumb>
<messagesenderidentifier>SAAVPROD</messagesenderidentifier>
<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20130125151452</messagedate>
</ichicsrmessageheader>
<safetyreport>
<safetyreportversion>1</safetyreportversion>
<safetyreportid>IT-SANOFI-AVENTIS-2013SA001426</safetyreportid>
<primarysourcecountry>IT</primarysourcecountry>
<occurcountry>IT</occurcountry>
<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>20130125</transmissiondate>
<reporttype>1</reporttype>
<serious>1</serious>
<seriousnessdeath>2</seriousnessdeath>
<seriousnesslifethreatening>2</seriousnesslifethreatening>
<seriousnesshospitalization>1</seriousnesshospitalization>
<seriousnessdisabling>2</seriousnessdisabling>
<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
<receivedateformat>102</receivedateformat>
<receivedate>20130108</receivedate>
<receiptdateformat>102</receiptdateformat>
<receiptdate>20130108</receiptdate>
<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
<companynumb>IT-SANOFI-AVENTIS-2013SA001426</companynumb>
<duplicate>1</duplicate>
<reportduplicate>
<duplicatesource>ITA-AIFA</duplicatesource>
<duplicatenumb>187756</duplicatenumb>
</reportduplicate>
<reportduplicate>
<duplicatesource>PCP_DAIICHI SANKYO_JPN</duplicatesource>
<duplicatenumb>IT2013/00030</duplicatenumb>
</reportduplicate>
<primarysource>
<reporterorganization>Italian Medicines Agency</reporterorganization>
<reportercountry>IT</reportercountry>
<qualification>3</qualification>
</primarysource>
<primarysource>
<reportercountry>IT</reportercountry>
<qualification>1</qualification>
</primarysource>
<primarysource>
<reportercountry>IT</reportercountry>
<qualification>2</qualification>
</primarysource>
<sender>
<sendertype>1</sendertype>
<senderorganization>sanofi-aventis</senderorganization>
<senderdepartment>US Affiliate Pharmacovigilance</senderdepartment>
<sendergivename>Barbara</sendergivename>
<senderfamilyname>Rullo</senderfamilyname>
<senderstreetaddress>55A-435 55 Corporate Drive</senderstreetaddress>
<sendercity>Bridgewater</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>08807</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>9089816698</sendertel>
<sendertelcountrycode>1</sendertelcountrycode>
<senderfax>9089877894</senderfax>
<senderfaxcountrycode>1</senderfaxcountrycode>
<senderemailaddress>Barbara.Rullo@sanofi-aventis.com</senderemailaddress>
</sender>
<receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Center for Drug Evaluation and Research</receiverdepartment>
<receiverstreetaddress>5600 Fishers lane</receiverstreetaddress>
<receivercity>Rockville</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20857</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>3018273237</receivertel>
<receivertelcountrycode>1</receivertelcountrycode>
<receiveremailaddress>aersesub@cder.fda.gov</receiveremailaddress>
</receiver>
<patient>
<patientinitial>CP</patientinitial>
<patientbirthdateformat>102</patientbirthdateformat>
<patientbirthdate>19390722</patientbirthdate>
<patientonsetage>73</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientagegroup>6</patientagegroup>
<patientsex>1</patientsex>
<resultstestsprocedures>Date: unknown
osteo-tendon echography was performed.</resultstestsprocedures>
<medicalhistoryepisode>
<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
<patientepisodename>10055217</patientepisodename>
<patientmedicalcontinue>1</patientmedicalcontinue>
</medicalhistoryepisode>
<medicalhistoryepisode>
<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
<patientepisodename>10066551</patientepisodename>
<patientmedicalcontinue>1</patientmedicalcontinue>
</medicalhistoryepisode>
<medicalhistoryepisode>
<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
<patientepisodename>10038683</patientepisodename>
<patientmedicalcontinue>1</patientmedicalcontinue>
</medicalhistoryepisode>
<reaction>
<primarysourcereaction>tendonitis</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10043255</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20130103</reactionstartdate>
<reactionfirsttime>8</reactionfirsttime>
<reactionfirsttimeunit>804</reactionfirsttimeunit>
<reactionoutcome>6</reactionoutcome>
</reaction>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>CARVEDILOL</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>18</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugadministrationroute>048</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10019277</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130108</drugenddate>
<drugtreatmentduration>14</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<drugadditional>Form:Unknown</drugadditional>
<activesubstance>
<activesubstancename>CARVEDILOL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>TRIATEC</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>2</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugdosageform>TABLET</drugdosageform>
<drugadministrationroute>048</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10020772</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130108</drugenddate>
<drugtreatmentduration>14</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<activesubstance>
<activesubstancename>RAMIPRIL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>LASIX</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugauthorizationnumb>NDA 16-273</drugauthorizationnumb>
<drugstructuredosagenumb>25</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugdosageform>TABLET</drugdosageform>
<drugadministrationroute>048</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10057097</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130108</drugenddate>
<drugtreatmentduration>14</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<activesubstance>
<activesubstancename>FUROSEMIDE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>LANSOPRAZOLE</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>30</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugadministrationroute>048</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10057097</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130108</drugenddate>
<drugtreatmentduration>14</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<drugadditional>Form:Unknown</drugadditional>
<activesubstance>
<activesubstancename>LANSOPRAZOLE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>LEVOFLOXACIN</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>500</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugadministrationroute>042</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10035664</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130101</drugenddate>
<drugtreatmentduration>7</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>1</actiondrug>
<drugadditional>Form:Unknown</drugadditional>
<activesubstance>
<activesubstancename>LEVOFLOXACIN</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>METFORMIN</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>100</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugadministrationroute>048</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10067585</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20121229</drugenddate>
<drugtreatmentduration>4</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<drugadditional>Form:Unknown</drugadditional>
<activesubstance>
<activesubstancename>METFORMIN HYDROCHLORIDE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>NITRO-DUR</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>10</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugdosagetext>strength: 10 mg/die</drugdosagetext>
<drugdosageform>TRANSDERMAL PATCH</drugdosageform>
<drugadministrationroute>062</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10057097</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130108</drugenddate>
<actiondrug>5</actiondrug>
<activesubstance>
<activesubstancename>GLYCERYL TRINITRATE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>CARDIOASPIRIN</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>100</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugdosageform>GASTRO-RESISTANT TABLET</drugdosageform>
<drugadministrationroute>048</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10053468</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20121229</drugenddate>
<drugtreatmentduration>4</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<activesubstance>
<activesubstancename>ACETYLSALICYLIC ACID</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>BRONCOVALEAS</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugdosagetext>form: solution for nebulization
strength: 0.5 %</drugdosagetext>
<drugadministrationroute>065</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10035664</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20130101</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130107</drugenddate>
<drugtreatmentduration>13</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<drugadditional>Form:Unknown</drugadditional>
<activesubstance>
<activesubstancename>SALBUTAMOL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>CLENIL</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugstructuredosagenumb>100</drugstructuredosagenumb>
<drugstructuredosageunit>003</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugdosagetext>route: intranasal</drugdosagetext>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10035664</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20121226</drugstartdate>
<drugstartperiod>8</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130101</drugenddate>
<drugtreatmentduration>7</drugtreatmentduration>
<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
<actiondrug>5</actiondrug>
<drugadditional>Form:Unknown</drugadditional>
<activesubstance>
<activesubstancename>BECLOMETASONE DIPROPIONATE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>CLEXANE</medicinalproduct>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20130102</drugstartdate>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130104</drugenddate>
<activesubstance>
<activesubstancename>ENOXAPARIN SODIUM</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>IDROPLURIVIT</medicinalproduct>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20130102</drugstartdate>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20130104</drugenddate>
<activesubstance>
<activesubstancename>VITAMINS NOS</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization>2</drugcharacterization>
<medicinalproduct>TORVAST</medicinalproduct>
<activesubstance>
<activesubstancename>ATORVASTATIN CALCIUM</activesubstancename>
</activesubstance>
</drug>
<summary>
<narrativeincludeclinical>This serious unsolicited case from Italy (local reference no.: 2013-IT-000056) was received on 08-Jan-2013 from Health Authorities of Italy (Italian Medicines Agency; regulatory no.: 187756) via a physician and concerns a 73-years-old male patient who experienced levofloxacin induced bilateral Achilles tendon tendonitis whilst receiving levofloxacin for pneumonia.

On 26-Dec-2012, the patient commenced therapy with intravenous levofloxacin at a dose of 500 mg daily (form, lot/batch number and expiration date unknown). After 8 days of treatment on 03-Jan-2013, he experienced levofloxacin induced bilateral Achilles tendon tendonitis. Therapy with levofloxacin was discontinued on 04-Jan-2013. The patient was maintained at rest and an osteo-tendon echography was performed. No information regarding the corrective conduct was provided.

Outcome for the event was unknown.

The patient&#xc2bf;s concomitant medications included salbutamol (Broncovaleas) and beclometasone dipropionate (Clenil) both for pneumonia , ramipril (Triatec) for essential hypertension, furosemide (Lasix) for diuretic effect, lansoprazole for gastroesophageal reflux disease, carvedilol for cardiomegaly, metformin hydrochloride (Metformin) for diabetes mellitus type 2, glyceryl trinitrate (Nitro DUR) for decubitus angina, acetylsalicylic acid (Cardioaspirin), enoxaparin sodium (Clexane) and idroplurivit. The patient&#xc2bf;s concurrent conditions included dilatative ischemic cardiomyopathy, diabetes mellitus, chronic atrial fibrillation and restrictive respiratory deficit. No past drugs were reported.

A further evaluation was planned for 09-Jan-2013.

Additional information was received on 09-Jan-2013 from local health authority.
Route of levofloxacin was changed from oral to intravenous. Suspect drugs salbutamol (Broncovaleas), beclometasone dipropionate (Clenil), ramipril (Triatec), furosemide (Lasix), lansoprazole, carvedilol, metformin hydrochloride (Metformin), glyceryl trinitrate (Nitro DUR) and acetylsalicylic acid (Cardioaspirin) was considered concomitant medication in this follow up. Concomitant medications enoxaparin sodium (Clexane) and idroplurivit were added.

Additional information was reported by GlaxoSmithKline to our license partner Daiichi Sankyo on 21-Jan-2013 as case number ID (B085854A).
In follow-up information previously reported concomitant medications (beclomethasone dipropionate (Clenil), salbutamol sulphate (Broncovaleas), aspirin (Cardioaspirin), frusemide (Lasix), ramipril (Triatec), nitroglycerine (Nitrodur), metformin hydrochloride (Metformina), lansoprazole and carvedilol) were captured as co-suspects.

This case was reported by a pharmacist via the Italian regulatory authority and described the occurrence of suspected bilateral achilleus tendonitis in a 73-year-old male patient who received levofloxacin (Levoxacin) for pneumonia.

Concurrent medical conditions included atrial fibrillation, ischemic heart disease, hypertension, diabetes mellitus type 2 and respiratory disease. Co-suspect medication included beclomethasone dipropionate (Clenil), salbutamol sulphate (Broncovaleas), aspirin (Cardioaspirin), frusemide (Lasix), ramipril (Triatec), nitroglycerine (Nitrodur), metformin hydrochloride (Metformina), lansoprazole and carvedilol.

On 26 December 2012, the patient started treatment with levofloxacin (oral) at a total daily dose of 500 mg, beclomethasone dipropionate (intranasal) at a total daily dose of 100mg, aspirin (oral) at a total daily dose of 100mg, frusemide (oral) at a total daily dose of 25mg, ramipril (oral) at a total daily dose of 2mg, nitroglycerine (transdermal) at a total daily dose of 10mg, metformin hydrochloride (oral) at a total daily dose of 100mg, lansoprazole (oral) at a total daily dose of 30mg and carvedilol (oral) at a total daily dose of 18mg. On 1 January 2013, the patient started treatment with salbutamol sulphate at an unspecified dose. Approximately 8 days after starting levofloxacin on 3 January 2013, the patient experienced suspected bilateral achilleus tendonitis. The patient was hospitalised. At the time of reporting, the outcome of the event was unknown. The regulatory authority reported that the event was possibly related to treatment with levofloxacin, beclomethasone dipropionate, salbutamol sulphate, aspirin, frusemide, ramipril, nitroglycerine, metformin hydrochloride, lansoprazole and carvedilol.</narrativeincludeclinical>
<sendercomment>Sanofi-aventis company comment dated 09-Jan-2013: The casual role cannot be assessed in isolation as the patient is taking multiple suspect drugs.

Sanofi-Aventis company comment dated 24-Jan-13: Although the role of carvedilol,ramipril,furosemide,lansoprazole cannot be denied for the event of tendonitis however contributory role of co-suspect drugs cannot be underestimated either.</sendercomment>
</summary>
</patient>
</safetyreport>
</ichicsr>
